Black Diamond Therapeutics, Inc. (BDTX)
Develops targeted cancer drugs designed to attack specific genetic mutations in tumors.
$1.75+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-32.4%
The outlook
BDTX is trading near its 52-week lows, well below both its 50- and 200-day averages. Analyst coverage shows a significant gap, with the average price target implying substantial upside from current levels, though the overall sentiment leans bearish. The stock remains in a weak technical position near the bottom of its recent range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +463% vs current price
Analyst price target
~12-month · 7 analysts$9.86average target+463.3% vs now
Now $1.75
Low $7.00High $14.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$100.3M
52-wk high
$4.94
52-wk low
$1.60
50-day avg
$2.04
200-day avg
$2.69
Trailing P/E
—